Overview Performance Dividends Peer Group Options

(AROC) AroCell - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0003883990

AROC: Cancer Tests, Blood Tests, Urine Tests, Immunoassay Kits

AroCell AB (publ) is a Swedish in vitro diagnostics company specializing in the development and commercialization of innovative diagnostic tests for oncological and infectious diseases. The company offers a portfolio of products, including UBC Rapid, a point-of-care test for bladder cancer diagnosis and monitoring; AroCell TK 210 ELISA, a biomarker assay for tumor cell detection; and TUBEX TF, a diagnostic test for acute typhoid fever. AroCell AB (publ) was founded in 2000 under the name Xi Bao Research AB and rebranded to its current name in 2006. Headquartered in Stockholm, Sweden, the company operates at the intersection of precision medicine and infectious disease diagnostics, leveraging its expertise in biomarkers and immunoassays to address unmet clinical needs.

The companys product pipeline is centered around improving diagnostic accuracy and patient outcomes in oncology and infectious diseases. UBC Rapid, its flagship product, provides rapid and reliable results for bladder cancer monitoring, enabling timely clinical decisions. AroCell TK 210 ELISA, which measures thymidine kinase 1 (TK1) levels, offers a minimally invasive biomarker for tumor cell activity, complementing traditional imaging and biopsy methods. TUBEX TF addresses the need for accurate and rapid diagnosis of typhoid fever, a significant public health burden in endemic regions. AroCell AB (publ) has established partnerships and collaborations to expand its market reach and drive adoption of its diagnostic solutions globally.

AroCell AB (publ) is listed on the Stockholm Stock Exchange under the ticker symbol AROC. The company operates within the Life Sciences Tools & Services sector, focusing on innovation in diagnostic testing. For more information, visit their website: https://www.arocell.com.

3-Month Forecast Based on the provided and , the following forecast is generated: - Technical Outlook: - The stock is currently trading at 0.51 SEK, slightly below its 20-day SMA of 0.58 and 50-day SMA of 0.52, indicating potential short-term weakness. - The 200-day SMA of 0.49 suggests that the stock is trading above its long-term trendline, which may provide support. - ATR of 0.04 indicates low volatility, suggesting that price movements may remain constrained in the near term. - Fundamental Outlook: - A market cap of 134.76M SEK reflects the companys moderate size in the diagnostics sector. - The P/E and Forward P/E of 0.00 indicate that the company is currently unprofitable, which may impact investor sentiment. - A P/B ratio of 1.10 suggests that the stock is trading slightly above its book value, indicating moderate valuation. - The P/S ratio of 2.35 reflects a reasonable valuation relative to its revenue generation. - A negative RoE of -34.98% highlights operational challenges and the need for profitability improvements. Conclusion: Over the next three months, AroCell AB (publ) is expected to experience sideways to slightly bearish price action, with potential support near the 200-day SMA of 0.49 SEK. Fundamental challenges, including profitability concerns, may weigh on investor sentiment, while the companys focus on innovative diagnostics could provide upside potential in the longer term.

Additional Sources for AROC Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

AROC Stock Overview

Market Cap in USD 12m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception

AROC Stock Ratings

Growth 5y -31.0%
Fundamental -12.3%
Dividend 0.0%
Rel. Strength Industry 48.4
Analysts -
Fair Price Momentum 0.49 SEK
Fair Price DCF -

AROC Dividends

No Dividends Paid

AROC Growth Ratios

Growth Correlation 3m 72.9%
Growth Correlation 12m 57.6%
Growth Correlation 5y -82.1%
CAGR 5y -9.18%
CAGR/Max DD 5y -0.10
Sharpe Ratio 12m -0.07
Alpha 43.08
Beta 0.19
Volatility 60.99%
Current Volume 74.6k
Average Volume 20d 159.5k
What is the price of AROC stocks?
As of March 14, 2025, the stock is trading at SEK 0.53 with a total of 74,643 shares traded.
Over the past week, the price has changed by +0.95%, over one month by -10.17%, over three months by +33.17% and over the past year by +48.04%.
Is AroCell a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, AroCell is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -12.34 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AROC as of March 2025 is 0.49. This means that AROC is currently overvalued and has a potential downside of -7.55%.
Is AROC a buy, sell or hold?
AroCell has no consensus analysts rating.
What are the forecast for AROC stock price target?
According to ValueRays Forecast Model, AROC AroCell will be worth about 0.5 in March 2026. The stock is currently trading at 0.53. This means that the stock has a potential upside of +1.89%.
Issuer Forecast Upside
Wallstreet Target Price 0.9 69.8%
Analysts Target Price - -
ValueRay Target Price 0.5 1.9%